94 related articles for article (PubMed ID: 22681975)
1. A membrane vesicle-based dual vaccine against melanoma and Lewis lung carcinoma.
Tian X; Zhu M; Tian Y; Ramm GA; Zhao Y; Nie G
Biomaterials; 2012 Sep; 33(26):6147-54. PubMed ID: 22681975
[TBL] [Abstract][Full Text] [Related]
2. [Allogeneic dendritic cell vaccine pulsed with heat shocked tumor cell lysate can enhance antitumor immunity].
You J; Wang CL; Hao XS
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2785-90. PubMed ID: 18167273
[TBL] [Abstract][Full Text] [Related]
3. Superior anti-tumor protection and therapeutic efficacy of vaccination with dendritic cell/tumor cell fusion hybrids for murine Lewis lung carcinoma.
Chen X; Liu Z; Huang Y; Li R; Zhang H; Dong S; Ge C; Zhang Z; Wang Y; Wang Y; Xue Y; Li Z; Song X
Autoimmunity; 2014 Feb; 47(1):46-56. PubMed ID: 24191684
[TBL] [Abstract][Full Text] [Related]
4. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
Pan JP; Weng YS; Wu QQ
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
[TBL] [Abstract][Full Text] [Related]
6. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
7. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
8. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses.
Du YC; Lin P; Zhang J; Lu YR; Ning QZ; Wang Q
Tissue Antigens; 2006 May; 67(5):368-76. PubMed ID: 16671943
[TBL] [Abstract][Full Text] [Related]
9. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
Zhang W; He L; Cao X
Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032
[TBL] [Abstract][Full Text] [Related]
10. Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells.
Fukushima S; Hirata S; Motomura Y; Fukuma D; Matsunaga Y; Ikuta Y; Ikeda T; Kageshita T; Ihn H; Nishimura Y; Senju S
J Immunother; 2009 Apr; 32(3):219-31. PubMed ID: 19242378
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell-directed lentivector vaccine induces antigen-specific immune responses against murine melanoma.
Yang HG; Hu BL; Xiao L; Wang P
Cancer Gene Ther; 2011 May; 18(5):370-80. PubMed ID: 21372855
[TBL] [Abstract][Full Text] [Related]
12. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells.
Savai R; Schermuly RT; Pullamsetti SS; Schneider M; Greschus S; Ghofrani HA; Traupe H; Grimminger F; Banat GA
Cancer Res; 2007 Jun; 67(11):5443-53. PubMed ID: 17545626
[TBL] [Abstract][Full Text] [Related]
13. [The anti-tumor activity of GM-CSF-modified lung cancer cell vaccine and its synergism in combination with chemotherapy].
Jiang HJ; Ren XB; Li H; Yu JP; Wei F; Ma MQ
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):808-12. PubMed ID: 18396635
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of murine Lewis lung cancer with recombinant interleukin-12].
Yin XL; Duan H; Peng ZP; Sun SL; Li SL
Ai Zheng; 2006 Sep; 25(9):1087-91. PubMed ID: 16965647
[TBL] [Abstract][Full Text] [Related]
15. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.
Machlenkin A; Goldberger O; Tirosh B; Paz A; Volovitz I; Bar-Haim E; Lee SH; Vadai E; Tzehoval E; Eisenbach L
Clin Cancer Res; 2005 Jul; 11(13):4955-61. PubMed ID: 16000595
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
[TBL] [Abstract][Full Text] [Related]
17. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antimetastatic effect of fetal liver kinase 1 extracellular domain and interferon-gamma fusion gene-modified dendritic cell vaccination.
Pan J; Heiser A; Marget M; Steinmann J; Kabelitz D
Gene Ther; 2005 May; 12(9):742-50. PubMed ID: 15729371
[TBL] [Abstract][Full Text] [Related]
19. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
[TBL] [Abstract][Full Text] [Related]
20. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
Cao X; Zhang W; He L; Xie Z; Ma S; Tao Q; Yu Y; Hamada H; Wang J
J Immunol; 1998 Dec; 161(11):6238-44. PubMed ID: 9834111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
